Sunshine Guojian Pharmaceutical (Shanghai) 過去の業績
過去 基準チェック /46
Sunshine Guojian Pharmaceutical (Shanghai) has been growing earnings at an average annual rate of 36.8%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 2.6% per year. Sunshine Guojian Pharmaceutical (Shanghai)'s return on equity is 7%, and it has net margins of 29.7%.
主要情報
36.8%
収益成長率
33.5%
EPS成長率
| Biotechs 業界の成長 | 11.3% |
| 収益成長率 | 2.6% |
| 株主資本利益率 | 7.0% |
| ネット・マージン | 29.7% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 29
We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings
Mar 31Recent updates
Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 29There's Reason For Concern Over Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) Massive 30% Price Jump
Oct 01What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You
Jul 25Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?
Jun 20If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity
May 24We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings
Mar 31Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 04収支内訳
Sunshine Guojian Pharmaceutical (Shanghai) の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 1,223 | 364 | 313 | 357 |
| 30 Jun 24 | 1,133 | 329 | 321 | 300 |
| 31 Mar 24 | 1,074 | 352 | 309 | 275 |
| 31 Dec 23 | 1,014 | 295 | 308 | 282 |
| 30 Sep 23 | 1,029 | 212 | 330 | 276 |
| 30 Jun 23 | 963 | 151 | 324 | 296 |
| 31 Mar 23 | 872 | 82 | 332 | 309 |
| 31 Dec 22 | 825 | 49 | 339 | 313 |
| 30 Sep 22 | 828 | 14 | 347 | 354 |
| 30 Jun 22 | 791 | -12 | 329 | 388 |
| 31 Mar 22 | 934 | 50 | 344 | 423 |
| 31 Dec 21 | 929 | 18 | 368 | 455 |
| 30 Sep 21 | 697 | -155 | 387 | 420 |
| 30 Jun 21 | 783 | -137 | 452 | 390 |
| 31 Mar 21 | 757 | -148 | 463 | 366 |
| 31 Dec 20 | 655 | -217 | 466 | 340 |
| 30 Sep 20 | 1,009 | 117 | 463 | 322 |
| 30 Jun 20 | 1,011 | 154 | 450 | 313 |
| 31 Mar 20 | 1,155 | 194 | 569 | 296 |
| 31 Dec 19 | 1,177 | 229 | 570 | 279 |
| 31 Dec 18 | 1,142 | 370 | 473 | 199 |
| 31 Dec 17 | 1,103 | 389 | 445 | 122 |
| 31 Dec 15 | 877 | 211 | 456 | 0 |
| 31 Dec 14 | 776 | 212 | 455 | 0 |
| 31 Dec 13 | 728 | 295 | 342 | 0 |
質の高い収益: 688336 has a large one-off gain of CN¥104.2M impacting its last 12 months of financial results to 30th September, 2024.
利益率の向上: 688336's current net profit margins (29.7%) are higher than last year (20.6%).
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 688336's earnings have grown significantly by 36.8% per year over the past 5 years.
成長の加速: 688336's earnings growth over the past year (71.5%) exceeds its 5-year average (36.8% per year).
収益対業界: 688336 earnings growth over the past year (71.5%) exceeded the Biotechs industry 0.08%.
株主資本利益率
高いROE: 688336's Return on Equity (7%) is considered low.